NCT05830097View on ClinicalTrials.gov

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

March 14, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

September 30, 2025

Conditions
Cancer, BreastCancer, LungCancer of PancreasCancer of EsophagusCancer Colorectal
Interventions
DRUG

CBP-1019

Light yellow to yellow loose lumps or powder；50mg/vial; Infusion for 90 minutes (± 10 minutes), once every 2 weeks.

Trial Locations (5)

11030

RECRUITING

Northwell Health Inc., Manhasset

22031

NOT_YET_RECRUITING

Next Oncology, Fairfax

32827

RECRUITING

Florida Cancer Specialists & Research Institute, Orlando

90805

RECRUITING

TOI Clinical Research LLC, Cerritos

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Coherent Biopharma (Hefei) Co., Ltd.

INDUSTRY